Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Nuvation Bio Inc. NUVB
$1.61
-$0.01 (-0.31%)
На 18:03, 12 мая 2023
+396.89%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
351753460.00000000
-
week52high
4.97
-
week52low
1.52
-
Revenue
0
-
P/E TTM
-5
-
Beta
0.62331200
-
EPS
-0.48000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 22 авг 2022 г. |
| BTIG | Neutral | Buy | 02 авг 2022 г. |
| BMO Capital | Market Perform | Outperform | 02 авг 2022 г. |
| RBC Capital | Outperform | Outperform | 11 мая 2022 г. |
| HC Wainwright & Co. | Buy | 04 мая 2022 г. | |
| Jefferies | Hold | Buy | 06 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| FALBERG KATHRYN E | A | 250000 | 43000 | 05 дек 2022 г. |
| FALBERG KATHRYN E | A | 207000 | 47000 | 02 дек 2022 г. |
| FALBERG KATHRYN E | A | 160000 | 84959 | 01 дек 2022 г. |
| FALBERG KATHRYN E | A | 75041 | 75041 | 30 ноя 2022 г. |
| Wentworth Kerry | A | 252000 | 252000 | 29 авг 2022 г. |
| Hattersley Gary | A | 400000 | 400000 | 29 авг 2022 г. |
| Liu Dongfang | A | 315000 | 315000 | 29 авг 2022 г. |
| Markel Stacy | A | 450000 | 450000 | 29 авг 2022 г. |
| Fox Jennifer A. | A | 480000 | 480000 | 29 авг 2022 г. |
| Hanley David C. | A | 450000 | 450000 | 29 авг 2022 г. |
Новостная лента
FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read Why
Benzinga
27 июн 2022 г. в 09:08
The FDA has placed a partial clinical hold on Nuvation Bio Inc's (NYSE: NUVB) Phase 1 dose-escalation study of NUV-422 in solid tumors. The company's Phase 1 trial began enrolling patients in December 2020 and, in recent months, was exploring higher doses to define a.